Ascendis Pharma A/S (NASDAQ:ASND) Trading Down 4.6% – What’s Next?

Shares of Ascendis Pharma A/S (NASDAQ:ASND) fell 4.6% during trading on Wednesday . The stock traded as low as $128.41 and last traded at $125.07. 13,803 shares were traded during trading, a decline of 97% from the average session volume of 420,233 shares. The stock had previously closed at $131.06.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Oppenheimer dropped their price objective on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. UBS Group assumed coverage on Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a “buy” rating and a $196.00 price objective for the company. TD Cowen lowered their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Finally, Wedbush reiterated an “outperform” rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and a consensus price target of $192.07.

Ascendis Pharma A/S Stock Down 2.9 %

The firm has a 50-day moving average price of $133.19 and a two-hundred day moving average price of $133.40. The company has a market capitalization of $7.72 billion, a P/E ratio of -15.74 and a beta of 0.65.

Institutional Trading of Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently bought and sold shares of ASND. Loomis Sayles & Co. L P grew its position in Ascendis Pharma A/S by 35.3% during the third quarter. Loomis Sayles & Co. L P now owns 184,623 shares of the biotechnology company’s stock worth $27,566,000 after buying an additional 48,120 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Ascendis Pharma A/S by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock worth $1,664,000 after purchasing an additional 4,338 shares in the last quarter. Valence8 US LP acquired a new position in shares of Ascendis Pharma A/S in the third quarter valued at $685,000. Nomura Asset Management Co. Ltd. lifted its position in Ascendis Pharma A/S by 42.5% in the third quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company’s stock worth $2,688,000 after purchasing an additional 5,371 shares during the period. Finally, Maven Securities LTD acquired a new stake in Ascendis Pharma A/S during the third quarter worth $7,466,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.